BrainsWay presented preliminary 12-month durability data for its SWIFT™ accelerated deep transcranial magnetic stimulation (dTMS) protocol at the Clinical TMS Society Annual Meeting, reporting a remission rate exceeding 80% one year post-treatment. Equally notable, the proportion of patients classified as experiencing severe functional impairment fell from 85% at baseline to 0% at the 12-month follow-up mark — a clinical endpoint that operators and formulators in the brain-health category will be watching closely as the line between device-based and ingredient-based neuromodulation continues to blur.
The SWIFT protocol is an accelerated dTMS regimen designed to compress treatment sessions into a shorter administration window, a structural departure from conventional once-daily TMS schedules. BrainsWay's proprietary H-coil technology targets deeper cortical and subcortical structures compared to standard figure-eight coil systems, a distinction the company argues is mechanistically relevant to the durability outcomes reported. The preliminary nature of the dataset warrants caution — full peer-reviewed publication with complete statistical disclosure has not yet been released — but the directional signal from the severe-impairment metric is significant.
For the functional foods and nutraceutical channel, the relevance is contextual but direct. The brain-health supplement category — encompassing nootropics, adaptogen-based stress formulations, omega-3 DHA finished formulations, and phosphatidylserine standardized extracts — is projected to remain among the fastest-growing segments in the broader condition-specific nutrition market. Consumer awareness of neurological wellness, accelerated post-pandemic, has elevated the competitive bar for structure-function claims. Brands competing in the cognitive and mood-support space increasingly face a market educated on clinical endpoints, not just mechanistic plausibility.
Device data like BrainsWay's durability findings indirectly set consumer expectation benchmarks. When clinical neuromodulation tools post 80%+ remission durability, supplement-sector operators are under greater implicit pressure to substantiate their own cognitive and mood claims with double-blind, placebo-controlled trial designs and peer-reviewed endpoints. Ingredient suppliers offering clinically validated actives — whether ashwagandha KSM-66, saffron extract, or lion's mane standardized to hericenones — are best positioned to help brand partners meet that rising evidentiary bar. Distribution through professional and clinical channels, where device and nutraceutical protocols increasingly intersect, amplifies this dynamic.
BrainsWay has not announced co-manufacturing partnerships or white-label licensing tied to the SWIFT data. The company's core commercial model remains capital-equipment-based, but the durability dataset strengthens its positioning in psychiatric and integrative health clinic networks — the same practitioner channels where premium functional supplement lines frequently compete for formulary placement and patient recommendation.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.